This is a preview and has not been published.

Relationship between serum Nesfatin-1, Adiponectin, Resistin Concentration, and Obesity with Type 2 Diabetes Mellitus


  • Baydaa Ahmed Abed National Diabetes Center, Mustansiriyah University, Baghdad, Iraq.
  • Layla Othman Farhan Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad Iraq.
  • Ashgan Slman Dawood National Diabetes Center, Mustansiriyah University, Baghdad, Iraq.



Adiponctin, HOMA-IR, Nesfatin-1, Resistin, Type 2 diabetes mellitus T2DM


            Diabetes mellitus caused by insulin resistance is prompted by obesity. Neuropeptide Nesfatin-1 was identified in several organs, including the central nervous system and pancreatic islet cells. Nesfatin-1 peptide appears to be involved in hypothalamic circuits that energy homeostasis and control food intake. Adiponectin is a plasma collagen-like protein produced by adipocytes that have been linked to the development of insulin resistance (IR), diabetes mellitus type 2 (DMT2), and cardiovascular disease (CVD). Resistin was first identified as an adipose tissue–specific hormone that was linked to obesity and diabetes.  The aim of this study was to estimate the relationship between human serum nesfatin-1, adiponectin, resistin concentration, and obesity with T2DM. The results show a significant increase in serum neisfatin-1 and resistin levels in the obese diabetic group compared to the non-obese diabetic group. Adiponectin levels had a highly significant decrease in the obese diabetic group compared to the non-obese group and obese control group. Serum Nesfatin-1 and some variables, there was a significant positive correlation with (BMI, insulin, HOMA-IR), and serum resistin had a significant positive correlation with (BMI, WC, TG, insulin, HOMA-IR).On the other hand, there was a negative correlation between serum adiponectin and (BMI, TG, and HOMA-IR). The present results suggest that nesftin-1 may have a role in controlling food intake as well as the development of IR in obese patients.


Download data is not yet available.


Zafar M, Irum S, Khan L, Sadia H, Roshan S, Rahman TU, et al. Prevalence of Diabetes Mellitus in Hepatitis C Patients in Wazirabad Tehsil of Gujranwala District of Pakistan: Hepatitis C in Diabetic patients. Baghdad Sci J. 2020; 17(4): 1154-1159.

Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 2018; 17(1): 1–14.

Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, et al. Obesity pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev. 2017; 38(4): 267–296.

Lomteva S V, Shkurat TP, Bugrimova ES, Zolotykh OS, Alexandrova AA, Karantysh G V. Violation of the Hormonal Spectrum in Polycystic Ovaries in Combination with Insulin Resistance. What is the Trigger: Insulin Resistance or Polycystic Ovary. Baghdad Sci J. 2022;19 (5):990-998.

Cercato C, Fonseca FA. Cardiovascular risk and obesity. Diabetol Metab Syndr. 2019; 11(74): 1-15.

Abozaid YJ, Zhang X, Mens MM, Ahmadizar F, Limpens M, Ikram MA, Rivadeneira F. Plasma circulating microRNAs associated with obesity, body fat distribution, and fat mass: the Rotterdam Study Int J Obes. 2022; 46(1): 2137–2144. .

Alotibi MN, Alnoury AM, Alhozali AM. Serum nesfatin-1 and galanin concentrations in the adult with metabolic syndrome: relationships to insulin resistance and obesity. Saudi Med J. 2019; 40(1):19-25.

Mogharnasi M, Taheri Chadorneshin H, Papoli-Baravati SA, Teymuri A. Effects of upper-body resistance exercise training on serum nesfatin-1 level, insulin resistance, and body composition in obese paraplegic men. Disabil Health J. 2019; 12(1):29–34.

Choi HM, Doss HM, Kim KS. Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci. 2020; 21(4): 1219.

Dong Y, Huang G, Wang X, Chu Z, Miao J, Zhou H. Meta-analysis of the association between adiponectin SNP 45, SNP 276, and type 2 diabetes mellitus. PLoS One. 2020; 15(10): 2-23.

Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J. 2020; 287(15): 3141-3149.

Lin Q, Johns RA. Resistin family proteins in pulmonary diseases. Am J Physiol Cell Mol Physiol. 2020; 319(3): 422–434.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-419.

Varagic J, Desvigne-Nickens P, Gamble-George J, Hollier L, Maric-Bilkan C, Mitchell M, et al. Maternal morbidity and mortality: Are we getting to the “heart” of the matter? J Women’s Heal. 2021; 30(2): 178–86.

Su Y, Zhang J, Tang Y, Bi F, Liu J-N. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun. 2010; 391(1): 1039–1042.

Tekin T, Cicek B, Konyaligil N. Regulatory peptide nesfatin-1 and its relationship with metabolic syndrome. Eurasian J Med. 2019; 51(3): 280-284.

Dong J, Xu H, Xu H, Wang P, Cai G, Song H, et al. Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLoS One. 2013; 8(12):1-8:

Farhan LO, Taha EM, Farhan AM. A Case control study to determine Macrophage migration inhibitor, and N-telopeptides of type I bone collagen Levels in the sera of osteoporosis patients. Baghdad Sci J. 2022, 19(4): 848-854.

Algül S, Dinçer E. The essential role of nesfatin-1 as a biological signal on the body systems. Kastamonu Med J. 2021;1(4):113–8.

Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol diabetes. 2012; 120(02): 91–5.

Anwar GM, Yamamah G, Ibrahim A, El-Lebedy D, Farid TM, Mahmoud R. Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance. Regul Pept. 2014; 188(10): 21–4.

Başar Ö, Akbal E, Köklü S, Koçak E, Tuna Y, Ekiz F, et al. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2012; 72(6): 479–83.

Huang J, Peng X, Dong K, Tao J, Yang Y. The association between insulin resistance, leptin, and Resistin and diabetic nephropathy in type 2 diabetes mellitus patients with different body mass indexes. Diabetes, Metab Syndr Obes Targets Ther. 2021; 24(14) 2357–65.

Liu W, Zhou X, Li Y, Zhang S, Cai X, Zhang R, et al. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: a population-based study. Medicine. 2020; 99(6):1-7.

Palumbo Piccionello A, Riccio V, Senesi L, Volta A, Pennasilico L, Botto R, et al. Adipose micro-grafts enhance tendinopathy healing in ovine model: An in vivo experimental perspective study. Stem Cells Transl Med. 2021; 10(11): 1544–60.

Abass EAA, Abed BA, Mohsin SN. Study Of Lysyl Oxidase-1 And Kidney Function In Sera Of Iraqi Patients With Diabetic Nephropathy. Biochem. Cell. Arch. 2021; 21(1) :1129-1132.

Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, et al. Dietary fiber‐derived short‐chain fatty acids: A potential therapeutic target to alleviate obesity‐related nonalcoholic fatty liver disease. Obes Rev. 2021; 22(11): e13316.

Guo Q, Cao S, Wang X. Adiponectin Intervention to Regulate Betatrophin Expression, Attenuate Insulin Resistance and Enhance Glucose Metabolism in Mice and Its Response to Exercise. Int J Mol Sci. 2022; 23(18): 1-12.

Ameen EM, Mohammed HY. Correlation between Tumor Necrosis Factor–Alfa and Anti-tyrosine Phosphatase with Obesity and Diabetes Type 2. Iraqi J Sci. 2022; 63(8): 3322–3331. .

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001; 86(5): 1930–1935.

Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20(6): 1595–1599.

Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001; 50(5): 1126–1133. .

Zhang Y, Chen G. The Link of Nutrient Fluxes to Hepatic Insulin Resistance at Gene Expression. Arch Gastroenterol Res. 2020; 1(3): 52–60.

Farhan LO. Determanation of Several Biochemical Parameters in Sera of Iraqi Patients with type 2 Diabetes. Baghdad Sci J. 2015; 12(2): 362-370.

Farhan LO, Mustafa SA, Mubder NS. Effect of Pregnancy on Selenium, Cupper, Zinc and Others Biochemical Feacture. Baghdad Sci J. 2013; 10(4): 1182-1189. :1182-1189

Hamid GS, Allawi AA, Ghudhaib KK. Correlation of Pentosidine with Kidney Diseases in Iraqi Patients with Diabetic Nephropathy. Iraqi J Sci. 2021; 62(10):3436–42.

Palit SP, Patel R, Jadeja SD, Rathwa N, Mahajan A, Ramachandran A V, et al. A genetic analysis identifies a haplotype at adiponectin locus: association with obesity and type 2 diabetes. Sci Rep. 2020; 10(1): 1–10. .

Ghaib ZJ, Ghudhaib KK, Mohsen FY. Assessment of Neuron Specific Enolase Level and some Related Biochemical Factors in Patients with Diabetic Peripheral Nerve Disorders. Indian J Forensic Med Toxicol. 2021; 15(3): 1494-1500 .

Abed BA, Al-AAraji SB, Salman IN. Estimation Of Galanin Hormone In Patients With Newly Thyroid Dysfunction In Type 2 Diabetes Mellitus. Biochem. Cell. Arch. 2021; 21 (1): 1317-1321.

Khaleel FM, N-Oda N, A Abed B. Disturbance of Arginase Activity and Nitric Oxide Levels in Iraqi Type 2 Diabetes Mellitus. Baghdad Sci J. 2018;15(2):189–191. DOI:

Abed BA, Hamid GS. Evaluation of Lipocalin-2 and Vaspin Levels in In Iraqi Women with Type 2 Diabetes Mellitus. Iraqi J Sci. 2022;63(11):650–658. DOI:

Al-Saad NNO, Khaleel FM, Al-Jumaili EFA. Purification and Characterization of Arginase from Serum of Healthy and Type II Diabetic Iraqi Patients. Indian J Forensic Med Toxicol. 2021; 15(3): 1194-1203.